INOTEK PHARMACEUTICALS CORP's ticker is and the CUSIP is 45780VAB8. A total of 9 filers reported holding INOTEK PHARMACEUTICALS CORP in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $5,785,000 | +1.5% | 4,000,000 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $5,700,000 | -27.6% | 4,000,000 | 0.0% | 0.00% | -40.0% |
Q4 2020 | $7,872,000 | +69.9% | 4,000,000 | 0.0% | 0.01% | +66.7% |
Q3 2020 | $4,633,000 | +4.5% | 4,000,000 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $4,432,000 | +5.1% | 4,000,000 | 0.0% | 0.00% | -25.0% |
Q1 2020 | $4,218,000 | -2.6% | 4,000,000 | 0.0% | 0.00% | +33.3% |
Q4 2019 | $4,329,000 | +9.6% | 4,000,000 | 0.0% | 0.00% | 0.0% |
Q3 2019 | $3,950,000 | -1.0% | 4,000,000 | 0.0% | 0.00% | +50.0% |
Q2 2019 | $3,989,000 | +0.6% | 4,000,000 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $3,967,000 | +320.2% | 4,000,000 | +300.0% | 0.00% | +100.0% |
Q4 2018 | $944,000 | -47.2% | 1,000,000 | -66.7% | 0.00% | 0.0% |
Q2 2017 | $1,788,000 | +1.0% | 3,000,000 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $1,770,000 | -43.3% | 3,000,000 | 0.0% | 0.00% | -66.7% |
Q4 2016 | $3,120,000 | -22.7% | 3,000,000 | 0.0% | 0.00% | 0.0% |
Q3 2016 | $4,036,000 | – | 3,000,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TFG Asset Management GP Ltd | 10,200,000 | $6,453,000 | 0.96% |
Springhouse Capital Management, LP | 2,000,000 | $1,215,000 | 0.48% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 9,700,000 | $5,784,000 | 0.40% |
Telemetry Investments, L.L.C. | 1,000,000 | $596,000 | 0.28% |
Bruce & Co., Inc. | 2,000,000 | $1,200,000 | 0.27% |
DAFNA Capital Management LLC | 600,000 | $369,000 | 0.26% |
Orbimed Advisors | 7,000,000 | $4,261,000 | 0.04% |
Baker Brothers Advisors | 5,000,000 | $2,978,000 | 0.03% |
Citadel Advisors | 8,500,000 | $5,143,000 | 0.00% |
DEUTSCHE BANK AG\ | 3,000,000 | $1,788,000 | 0.00% |